|
|
Research progress on clinical application and mechanism of Chinese medicine pair of Sparganii Rhizoma-Curcumae Rhizoma against tumor |
DU Fang1 YU Maixia2 HU Bofan1 XU Peng2 |
1.The First Clinical Medical College, Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712000, China;
2.Department of Oncology, Shaanxi Provincial Hospital of Chinese Medicine, Shaanxi Province, Xi’an 710000, China |
|
|
Abstract Sparganii Rhizoma-Curcumae Rhizoma is a Chinese medicine pair commonly used in clinical medicine to promote qi and blood circulation and remove blood stasis, which is widely used in tumor treatment. Modern physicians often achieve the therapeutic goal of anti-cancer and tumor suppressive by Chinese medicine pair of Sparganii Rhizoma-Curcumae Rhizoma with softening hardness and dissipating mass, strengthening body resistance, and invigorating spleen. Modern pharmacological studies have proved that Chinese medicine pair of Sparganii Rhizoma-Curcumae Rhizoma can not only inhibit the proliferation and growth of tumor cells, interfere with the cell cycle, but also play an anti-tumor role by regulating the body’s immunity and anti-angiogenesis. However, at present, there are few studies on its combination with immunotherapy and targeted therapy, as well as on the generation of new substances and pharmacological effects in their compatibility. It is expected that the summary of this paper can provide ideas for further research of this Chinese medicine pair.
|
|
|
|
|
[1] 魏佳明,朱俊平,刘瑞连,等.古代经典名方中的药对运用思维探讨[J].天津中医药,2019,36(7):659-661.
[2] 国家药典委员会.中华人民共和国药典[S].一部.中国医药科技出版社,2020.
[3] 冯娅茹,张文婷,李二文,等.三棱化学成分及药理作用研究进展[J].中草药,2017,48(22):4804-4818.
[4] 谭静,林红强,王亚茹,等.三棱的化学成分、药理作用及临床应用研究进展[J].特产研究,2018,40(4):109-113.
[5] 陈晓军,韦洁,苏华,等.莪术药理作用的研究新进展[J].药学研究,2018,37(11):664-668,682.
[6] 陈赐慧,花宝金.张锡纯治疗肿瘤学术思想浅析[J].浙江中医药大学学报,2014,38(6):707-710.
[7] 王丽君,姚颖杰,阳照君,等.浅谈张锡纯先生运用三棱莪术的学术经验[J].中西医结合研究,2018,10(3):161-162.
[8] 张瑞清,赵唯含,雷根平,等.雷根平教授运用对药和角药治疗食管癌的经验[J].中国医药导报,2022,19(2):130-133.
[9] 李彬彬,姜敏,王超然,等.基于网络药理学探讨名老中医从瘀论治胃癌的作用机制[J].中国医药导报,2021,18(3):145-150,198.
[10] 苏会吉,彭子明,班少群,等.中西医结合治疗原发性肝癌的研究进展[J].湖南中医杂志,2022,38(4):189-192.
[11] 林丽珠,肖志伟,黄学武,等.原发性肝癌中西医结合诊疗实践回眸[J].中医肿瘤学杂志,2020,2(1):5-9.
[12] 党芸芝.裴氏软肝消痞丸对原发性肝癌介入术后患者无进展生存期和生存质量的影响[D].兰州:甘肃中医药大学,2016.
[13] 张强,邵明义,王琳琳,等.中医药治疗原发性肝癌研究述评[J].河南中医,2021,41(3):454-457.
[14] 董智平,张静喆.中医治疗胃癌研究进展[J].中国中西医结合外科杂志,2019,25(2):206-209.
[15] 赵航,戴玮.三棱莪术组方辅助治疗胃癌的临床效果研究[J].癌症进展,2019,17(8):925-928.
[16] 李成银,徐忆芳,赵井苓,等.健脾养血方联合化疗治疗胃癌的临床效果[J].中国医药导报,2022,19(8):89-92.
[17] 李潇潇,傅淑平,樊威,等.尤松鑫治疗结直肠癌经验探析[J].江苏中医药,2019,51(3):16-18.
[18] 董琴晖,金剑英,朱健,等.益气健脾化积方对晚期结肠癌患者免疫功能和生活质量的影响[J].浙江中西医结合杂志,2019,29(12):994-996.
[19] 玄海阳,李秀荣.中医药治疗卵巢癌研究概况[J].山东中医药大学学报,2022,46(2):271-276.
[20] 鲁佩佩,辛文秀.龙葵当归三棱汤治疗卵巢癌临床疗效及对免疫指标及炎性因子的影响[J].中华中医药学刊,2020,38(3):242-245.
[21] 杨闻君,糜晓梅.复方大七气汤联合TC方案治疗晚期卵巢癌疗效及对患者血清B7-H4、HE4水平的影响分析[J].四川中医,2021,39(8):153-156.
[22] 唐坤,霍炽文,欧阳志维.人附睾蛋白4在卵巢肿瘤患者中的表达水平与卵巢癌预后生存期的相关性研究[J].黑龙江医药,2022,35(3):677-679.
[23] Boice A,Bouchier-Hayes L. Targeting apoptotic caspases in cancer [J]. Biochim Biophys Acta Mol Cell Res,2020, 1867(6):118688.
[24] 唐杰.中药三棱有效成分筛选及其对胃癌MGC-803细胞增殖、凋亡的影响[D].衡阳:南华大学,2021.
[25] Rodrigues MA,Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis [J]. J Dermatolog Treat,2020,31(1):33-40.
[26] 张琰,马娜,王芳,等.莪术醇抑制JAK1/STAT3信号通路对肺癌细胞增殖、凋亡和侵袭的影响[J].临床医学研究与实践,2021,6(34):10-15.
[27] 欧凯西,刘捷,余成浩.基于网络药理学研究三棱-莪术药对抗子宫内膜癌的作用机制及实验验证[J].中药药理与临床,2022,38(4):73-79,143
[28] Huang X,Qian J,Li L,et al. Curcumol improves cisplatin sensitivity of human gastric cancer cells through inhibiting PI3K/AKT pathway [J]. Drug Dev Res,2020. Epub ahead of print.
[29] 华雯,高鸿彬.基于网络药理学探讨三棱-莪术药对治疗肝癌的作用机制[J].世界中医药,2022,17(5):687-691.
[30] 冯叶雯.基于网络药理学探讨三棱—莪术抗结肠癌作用及正常化肿瘤血管的实验研究[D].成都:成都中医药大学,2021.
[31] 刘绍壮.黑三棱内酯B通过活性氧介导的PI3K/AKT通路对前列腺癌发挥抗肿瘤作用的机制研究[D].沈阳:中国医科大学,2021.
[32] Tian N,Zheng Y,Li Z,et al. Histone Methylatic Modification Mediates the Tumor-suppressive Activity of Curcumol in Hepatocellular Carcinoma Via an Hotairezh2 Regulatory Axis [J]. J Ethnopharmacol,2021,280:114413.
[33] 张学非,朱萱萱,刘沈林,等.胃瘤安不同组方对人胃癌SGC-7901增殖、细胞周期和凋亡的影响[J].中国临床药理学与治疗学,2015,20(1):31-37.
[34] 周璐炜,王娟,陈旭.莪术醇抗T47D乳腺癌细胞增殖的作用机制研究[J].中国药房,2022,33(5):548-554.
[35] Ding Y,Zhuang S,Li Y,et al. Hypoxia-induced HIF1α dependent COX2 promotes ovarian cancer progress [J]. J Bioenerg Biomembr ,2021,53(4):441-448.
[36] 张莹,朱萱萱,王海丹.三棱莪术组方对人胃癌细胞SGC- 7901移植瘤裸鼠血清COX-2、VEGF和bFGF含量的影响[J].中华中医药学刊,2016,34(5):1196-1199.
[37] 张莹.三棱莪术方对消化道肿瘤的实验研究[D].南京:南京中医药大学,2016.
[38] 王小萍,徐冠玲,闫昕,等.“莪术-三棱”药对及其单味药水煎液的酚类和有机酸类化学成分分析[J].中国实验方剂学杂志,2020,26(23):171-179.
[39] 黄礼闯,赵梦亭,桑夏楠,等.三棱-莪术药对化学成分及药理作用研究进展[J].中华中医药杂志,2021,36(11):6612-6616. |
|
|
|